menu
back

Press releases

Jeantet advises Evonik in the acquisition of technology from METEX

Yvon Dréano , Vincent Netter , Jean-Guillaume Follorou , François-Xavier Simeoni , Olivier Angotti , Frédéric Sardain

(PARIS, 5 December 2016) – Evonik Industries AG of Germany and METabolic EXplorer (METEX) of France have agreed that Evonik will acquire a technology package from METEX to strengthen its biotechnology platform for amino acids, following an agreement signed today in Paris. The package includes METEX’s entire technology portfolio for the fermentative production of methionine, as well as patents, essential bacteria strains, and the inoLa™ brand. METEX considers that this agreement will underscore the relevance of METEX’s alternative technologies and will strengthen its ability to commercialize its other technologies. The transaction still requires authorization of the Evonik commitees.

The transaction also includes a back license agreement pertaining to certain patents to be transferred to Evonik; this agreement will allow METEX to continue using these patents for activities other than those relating to methionine. Furthermore, the companies intend to explore the possibility of a research and development cooperation agreement on the development of biotechnologically produced amino acids.

The Jeantet team included: Yvon Dréano, Vincent Netter (partners) and Charlotte Favaro on the corporate aspects; Frédéric Sardain (partner) and Pierre Nieuwyaer on the IP; Jean-Guillaume Follorou (partner) and François-Xavier Simeoni on the tax aspects; Olivier Angotti (partners) on labour and employment.

METEX was advised by: King & Wood Mallesons (Pierre-Louis Périn, Myriam Barry), Cabinet Barthélémy on labour and employment and Orrick on capital markets.